Clinical trial
A Single-Center, Single-Arm, Open-Label Phase I Clinical Trial Evaluating the Safety and Efficacy of RGB-5088 Islet Cell Injection in the Treatment of Type 1 Diabetes Mellitus
NCT06731218 is registered in ClinicalTrials.gov with Hangzhou Reprogenix Bioscience, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Center, Single-Arm, Open-Label Phase I Clinical Trial Evaluating the Safety and Efficacy of RGB-5088 Islet Cell Injection in the Treatment of Type 1 Diabetes Mellitus
- Lead sponsor
- Hangzhou Reprogenix Bioscience, Inc
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 17, 2025
- Completion date
- December 31, 2031
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.